Jiefang Sun

Biohybrid Fused-Cell Carrier for Programmable Therapeutic Modulation of Atherosclerosis.

Cardiovascular disease, driven primarily by atherosclerosis, remains a leading cause of global mortality. Lipid-lowering therapies reduce risk by less than one-third, leaving substantial residual inflammation compounded by rapid drug clearance and limited plaque targeting. Biomimetic systems such as cell-membrane coati...